Last reviewed · How we verify
ACEI
ACEI, marketed by Nanjing Children's Hospital, is an angiotensin-converting enzyme inhibitor used to manage conditions related to the renin-angiotensin-aldosterone system. The key strength of ACEI lies in its mechanism of action, which effectively inhibits ACE, a critical component in regulating blood pressure and fluid balance. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | ACEI |
|---|---|
| Also known as | Lotensin, angiotensin converting enzyme inhibitors, ACE inhibitor, ACEI and COVID, benazepril |
| Sponsor | Nanjing Children's Hospital |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pharmacological Optimization in Prevention in Heart Failure: A Sex-gap? (PHASE4)
- The STOP-MED CTRCD Trial (PHASE4)
- Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES) (NA)
- Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection
- A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease (PHASE1,PHASE2)
- Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN (PHASE2)
- Venous Congestion And Cognitive Dysfunction After Cardiac Surgery
- Chaigui Longmu Ejiao Paste for Ischemic Heart Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |